Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
GLLIR stock price ended at $0.25 on 星期四, after rising 19.05%
On the latest trading day Oct 30, 2025, the stock price of GLLIR rose by 19.05%, climbing from $0.22 to $0.25. During the session, the stock saw a volatility of 27.27%, with prices oscillating between a daily low of $0.22 and a high of $0.28. Notably, trading volume dropped by 86.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 336.3K shares were traded, equating to a market value of approximately $43.1M.